Advertisement

Advertisement

Most Read Stories
FDA Approves Atezolizumab for the First-Line Treatment of Patients With Metastatic NSCLC and High PD-L1 Expression
Atezolizumab Plus Bevacizumab vs Sorafenib in Treatment-Naive Patients With Unresectable Hepatocellular Carcinoma
FDA Approves Rucaparib in BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer
Neoadjuvant Atezolizumab Plus Chemotherapy for Resectable NSCLC
FDA Approves Olaparib for HRR Gene–Mutated Metastatic Castration-Resistant Prostate Cancer
FDA Approves Nivolumab/Ipilimumab for First-Line Treatment of Patients With Metastatic NSCLC and PD-L1 Tumor Expression ≥ 1%
Cancer Care at Tata Memorial Centre During the COVID-19 Pandemic
FDA Approves Ripretinib for Previously Treated Patients With Advanced Gastrointestinal Stromal Tumor
FDA Pipeline: Two Breakthrough Therapy Designations for Fam-Trastuzumab Deruxtecan-nxki, and More
10 Changes I Will Make in My Oncology Practice as a Result of COVID-19
Overall Survival With the Addition of ADT or Brachytherapy Boost to External-Beam Radiotherapy in Patients With Localized Prostate Cancer
COVID-19 Infection in Pediatric Patients With Cancer
New ASCO Guideline Addresses Head/Neck Squamous Cell Carcinoma of Unknown Primary
Selected Poster Presentations on Cancer Therapeutics and More
Do Men Treated With ADT for Prostate Cancer Have a Lower Risk of Acquiring COVID-19?
ASCO Special Report Provides Guidance to Oncology Practices on Resuming Cancer Care During the COVID-19 Pandemic
COVID-19 May Remain Stable for Hours to Days in Aerosols and on Surfaces
When Can Patients With Gleason 6 Prostate Cancer Safely Undergo Active Surveillance?
Antihistamines May Improve Survival Among Patients With Malignant Melanoma
Lessons Learned on Rotation at COVID-19 Inpatient Service at New York City Hospital

Advertisement

Advertisement



Advertisement